Literature DB >> 9226151

The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.

K Nishida1, A Tamura, N Nakazawa, Y Ueda, T Abe, F Matsuda, K Kashima, M Taniwaki.   

Abstract

Chromosome rearrangement of 14q32.33 has recurrently occurred with variable partner sites, including 11q13.3, 8q24.1, 18q21.3, and 6p21.1 in multiple myeloma (MM). To assess the actual incidence of 14q32.33 translocation and to elucidate its implication in the pathogenesis of MM, we studied 42 patients with MM, plasma cell leukemia, or plasmacytoma and 5 with monoclonal gammopathy with undetermined significance (MGUS) by G-banding and molecular cytogenetic methods. Using double-color fluorescence in situ hybridization (DCFISH) with 2 Ig heavy chain (IgH) gene probes, a yeast artificial chromosome (YAC) clone containing variable region, and a phage clone containing gamma constant region, 14q32.33 translocation was detected as split signals of the IgH gene in 31 patients with plasma cell malignancies and 3 with MGUS. In contrast, of 40 patients who were assessed by G-banding, 3 (7.5%) showed the 14q+ chromosome. DCFISH detected a split of the IgH gene on interphase nuclei in 34 (73.9%) of 46 patients analyzed, whereas on metaphase spreads, it was in 22 (51.2%) of 43 patients analyzed. Interphase DCFISH was particularly useful to detect 14q32.33 translocation in 17 (65.4%) of 26 patients with normal karyotypes. Donor sites were identified in 11 of 22 patients demonstrated as carrying 14q32.33 translocation by metaphase FISH. Chromosome t(11;14)(q13.3; q32.33) was detected in 5 patients, t(8;14)(q24.1;q32.33) in 2, t(14;18)(q32.33;q21.3) in 2, and t(7;14)(q32.1;q32.33) in 1. A complex 14q32.33 translocation involving 3q and 16q24 was detected in 1 patient. Myeloma cells with t(7;14) showed myelomonocytoid surface antigen. Because rearrangements of 14q32.33 were closely associated with translocation of proto-oncogenes into the IgH gene, our findings indicate that 14q32.33 translocation with various partner chromosomes is a critical event in the pathogenesis of MM and MGUS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9226151

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.

Authors:  Miki Kiyota; Tsutomu Kobayashi; Shinichi Fuchida; Mio Yamamoto-Sugitani; Muneo Ohshiro; Yuji Shimura; Shinsuke Mizutani; Hisao Nagoshi; Nana Sasaki; Ryuko Nakayama; Yoshiaki Chinen; Natsumi Sakamoto; Hitoji Uchiyama; Yosuke Matsumoto; Shigeo Horiike; Chihiro Shimazaki; Junya Kuroda; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2012-03-17       Impact factor: 2.490

2.  The unbalanced chromosomal translocation der(15)t(1;15)(q21;p13) in multiple myeloma.

Authors:  Sonoko Nakano; Kyoko Namura; Ryo Uchida; Shin-ichi Fuchida; Akira Okano; Masashi Okamoto; Chihiro Shimazaki
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

3.  Thirty patients with primary plasma cell leukemia: a single center experience.

Authors:  Milica Colović; Gradimir Janković; Nada Suvajdzić; Natasa Milić; Vesna Dordević; Snezana Janković
Journal:  Med Oncol       Date:  2007-10-10       Impact factor: 3.064

4.  Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.

Authors:  Y Shou; M L Martelli; A Gabrea; Y Qi; L A Brents; A Roschke; G Dewald; I R Kirsch; P L Bergsagel; W M Kuehl
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

Review 5.  Genetics of multiple myeloma: another heterogeneity level?

Authors:  Jill Corre; Nikhil Munshi; Hervé Avet-Loiseau
Journal:  Blood       Date:  2015-01-27       Impact factor: 22.113

6.  A practical approach to the detection of prognostically significant genomic aberrations in multiple myeloma.

Authors:  Zhong Chen; Bonnie Issa; Shiang Huang; Emily Aston; Jia Xu; Margaret Yu; Arthur R Brothman; Martha Glenn
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

7.  Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).

Authors:  G Pruneri; S Fabris; L Baldini; N Carboni; S Zagano; M A Colombi; G Ciceri; L Lombardi; M Rocchi; R Buffa; A T Maiolo; A Neri
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

Review 8.  Multistep tumorigenesis of multiple myeloma: its molecular delineation.

Authors:  Shinsuke Iida; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

9.  Close relation between 14q32/IGH translocations and chromosome 13 abnormalities in multiple myeloma: a high incidence of 11q13/CCND1 and 16q23/MAF.

Authors:  Madoka Takimoto; Kohei Ogawa; Yo Kato; Tasuku Saito; Takao Suzuki; Michiko Irei; Yasushi Shibuya; Yoshinori Suzuki; Masayuki Kato; Yasuyuki Inoue; Masatomo Takahashi; Hiroki Sugimori; Ikuo Miura
Journal:  Int J Hematol       Date:  2008-02-16       Impact factor: 2.490

10.  Distinct retroelement classes define evolutionary breakpoints demarcating sites of evolutionary novelty.

Authors:  Mark S Longo; Dawn M Carone; Eric D Green; Michael J O'Neill; Rachel J O'Neill
Journal:  BMC Genomics       Date:  2009-07-24       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.